Plasmid DNA Preparation Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Research Grade Plasmid DNA Preparation, Industrial Grade Plasmid DNA Preparation, Pre-clinical Grade Plasmid DNA Preparation, GLP Plasmid DNA Preparation, Others), By Application (Gene Therapy, Cell Therapy, Vaccinology, Clinical Research, Others), By End User (Pharmaceutical and Biopharmaceutical Companies, CROs and CMOs, Academic and Research Institutes) and Region Forecast 2019-2030  

Plasmid DNA Preparation Market size was valued at US$ 1,734.7 million in 2023 and is projected to reach US$ 4,261.4 million by 2030 at a CAGR of 13.7% from 2024-2030. the forecast years to reach The market is driven by several factors such as increasing demand for plasmid DNA (pDNA) in cell and gene therapy, rising prevalence of chronic diseases, technological advancements, and growing government support.

pDNA is a crucial component in cell and gene therapies, which are rapidly emerging as promising treatments for a wide range of diseases, and this is fueling the demand for pDNA preparation kits and services, also the growing prevalence of chronic diseases like cancer, neurological disorders, and genetic diseases is leading to an increased need for novel therapeutic approaches, including gene therapy, this in turn is driving the demand for pDNA. Advancements in plasmid manufacturing technologies, such as automation and continuous processing, are making pDNA production faster, more efficient, and cost-effective, this is making pDNA-based therapies more accessible to patients.

Additionally, the governments around the world are increasingly recognizing the potential of gene therapy and are providing funding for research and development in this fiel and this is creating a favorable environment for the growth of the market. The opportunities in the market are significant such as development of novel plasmid delivery systems, growing adoption of personalized medicine, and increasing focus on emerging markets. Increasing Demand for GMP-grade plasmid DNA, growing adoption of single-use technologies, and automation and continuous processing are the trends in the market. However, the constraints in the market will hinder the market growth such as stringent regulatory requirements, high cost of plasmid DNA manufacturing, and lack of skilled workforce.

Plasmid DNA Preparation Market Key Developments

• In November 2023, Ajinomoto Co., Inc. announced its decision to acquire all units of Forge Biologics Holdings, LLC, a US-based gene therapy Contract Development and Manufacturing Organization (CDMO), for approximately US$ 554 million. This acquisition was part of Ajinomoto’s strategic growth plan in the healthcare sector, leveraging its proprietary “AminoScience” platform. The acquisition aimed to accelerate growth through expansion into gene therapy CDMO, among other areas.
• In June 2021, Charles River Laboratories International, Inc. completed the acquisition of Vigene Biosciences, Inc. The acquisition was aimed at enhancing Charles River’s gene therapy capabilities, particularly in the high-growth cell and gene therapy CDMO sector.